Clinical Trial Update: Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) [Phase 3]

View source ↗

Summary

Phase 3 cardiovascular trial investigating reduction in recurrent major cardiovascular disease events in atherosclerosis; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Atherosclerosis | Phase 3 | Status: COMPLETED | Results posted: 2020-01-22